Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00005
|
|||||
Drug Name |
L-glutamic acid
|
|||||
Synonyms |
(2S)-2-Aminopentanedioic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid; 2-Aminoglutaric acid; 2-aminopentanedioic acid; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique; Acide glutamique [INN-French]; Acido glutamico; Acido glutamico [INN-Spanish]; Acidum glutamicum; Acidum glutamicum [INN-Latin]; Acidum glutaminicum; Aciglut; Alpha-Aminoglutaric acid (VAN); Alpha-Glutamic acid; Alpha-L-Glutamic acid polymer; Alpha-aminoglutaric acid; D-Glutamiensuur; E 620; GLUTAMIC ACID; Glu; Glusate; Glut; Glutacid; Glutamate; Glutamic Acid (L-glutamic acid); Glutamic Acid [USAN:INN]; Glutamic acid (H-3); Glutamic acid (VAN); Glutamic acid polymer; Glutamic acid, L-(7CI,8CI); Glutamic acid, L-, peptides; Glutamicol; Glutamidex; Glutaminic acid; Glutaminic acid (VAN); Glutaminol; Glutaton; Gulutamine; Gulutamine (USP); H-Glu-OH; L-(+)-glutamic acid; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid hydrochloride; L-Glutamic acid, homopolymer; L-Glutamic acid, homopolymer (9CI); L-Glutaminic acid; L-Glutaminsaeure; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; L-glu; L-glutamate; POLYGLUTAMIC ACID; Poly(alpha-L-glutamic acid); Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Indigestion [ICD11: DD90] | Approved | [1] | |||
Schizophrenia [ICD11: 6A20] | Approved | [1] | ||||
Therapeutic Class |
Dietary supplement
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C5H9NO4
|
|||||
Canonical SMILES |
C(CC(=O)O)C(C(=O)O)N
|
|||||
InChI |
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
|
|||||
InChIKey |
WHUUTDBJXJRKMK-VKHMYHEASA-N
|
|||||
CAS Number |
CAS 56-86-0
|
|||||
Pharmaceutical Properties | Molecular Weight | 147.13 | Topological Polar Surface Area | 101 | ||
Heavy Atom Count | 10 | Rotatable Bond Count | 4 | |||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
-3.7
|
|||||
PubChem CID | ||||||
PubChem SID |
10527679
, 11110117
, 11110137
, 11113412
, 11528393
, 11538992
, 14710662
, 14716143
, 14719817
, 14719819
, 15297417
, 16918839
, 17404216
, 17422134
, 17422293
, 24846358
, 24872908
, 24895052
, 24895223
, 24895340
, 24901609
, 24902257
, 26746616
, 26751652
, 3327
, 34674977
, 46391925
, 627126
, 7847075
, 7887923
, 7979423
, 8023666
, 8026291
, 8026293
, 8143737
, 8172949
, 820094
, 820617
, 822192
, 822517
, 822724
, 822932
, 823119
, 825074
, 826975
, 828108
, 841758
, 854467
, 854468
, 854502
|
|||||
ChEBI ID |
ChEBI:16015
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | AGT1 | Transporter Info | Sodium-independent aspartate/glutamate transporter 1 | Substrate | [2] | |
ARALAR1 | Transporter Info | Calcium-binding mitochondrial carrier protein Aralar1 | Substrate | [3] | ||
ARALAR2 | Transporter Info | Calcium-binding mitochondrial carrier protein Aralar2 | Substrate | [4] | ||
EAAT1 | Transporter Info | Excitatory amino acid transporter 1 | Substrate | [5] | ||
EAAT2 | Transporter Info | Excitatory amino acid transporter 2 | Substrate | [6] | ||
EAAT3 | Transporter Info | Excitatory amino acid transporter 3 | Substrate | [7] | ||
EAAT4 | Transporter Info | Excitatory amino acid transporter 4 | Substrate | [5] | ||
EAAT5 | Transporter Info | Excitatory amino acid transporter 5 | Substrate | [5] | ||
GC1 | Transporter Info | Mitochondrial glutamate carrier 1 | Substrate | [8] | ||
GC2 | Transporter Info | Mitochondrial glutamate carrier 2 | Substrate | [9] | ||
OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [10] | ||
OATP2B1 | Transporter Info | Organic anion transporting polypeptide 2B1 | Substrate | [11] | ||
OCTL3 | Transporter Info | Organic cation transporter-like 3 | Substrate | [12] | ||
SLC38A10 | Transporter Info | Putative sodium-coupled neutral amino acid transporter 10 | Substrate | [13] | ||
SLC38A8 | Transporter Info | Putative sodium-coupled neutral amino acid transporter 8 | Substrate | [14] | ||
SLC7A11 | Transporter Info | Cystine/glutamate transporter | Substrate | [15] | ||
VGLUT1 | Transporter Info | Vesicular glutamate transporter 1 | Substrate | [16] | ||
VGLUT2 | Transporter Info | Vesicular glutamate transporter 2 | Substrate | [16] | ||
VGLUT3 | Transporter Info | Vesicular glutamate transporter 3 | Substrate | [16] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | EAAT2 | Transporter Info | Km = 21 microM | Human embryonic kidney cells (HEK293)-EAAT2 | [17] | |
EAAT2 | Transporter Info | Km = 21 microM | Human embryonic kidney cells (HEK293)-EAAT2 | [18] | ||
EAAT3 | Transporter Info | Km = 9.9 microM | Human embryonic kidney cells (HEK293)-EAAT3 | [18] | ||
EAAT3 | Transporter Info | Km = 25 microM | Human embryonic kidney cells (HEK293)-EAAT3 | [17] | ||
References | ||||||
1 | L-glutamic acid was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80. | |||||
3 | Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis. Mol Neurobiol. 2016 Apr;53(3):1579-1588. | |||||
4 | Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47. | |||||
5 | The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20. | |||||
6 | EAAT2 (GLT-1; slc1a2) glutamate transporters reconstituted in liposomes argues against heteroexchange being substantially faster than net uptake. J Neurosci. 2014 Oct 1;34(40):13472-85. | |||||
7 | Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53. | |||||
8 | Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005 Feb;76(2):334-9. | |||||
9 | The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC25A18) | |||||
10 | The role of the intracellular glutamate gradient in driving organic anion transporter function. | |||||
11 | The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20) | |||||
12 | SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51. | |||||
13 | The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746. | |||||
14 | Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia. Mol Genet Genomic Med. 2017 Feb 26;5(3):202-209. | |||||
15 | The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249. | |||||
16 | Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65. | |||||
17 | Chemoenzymatic synthesis of a series of 4-substituted glutamate analogues and pharmacological characterization at human glutamate transporters subtypes 1-3. J Med Chem. 2005 Dec 15;48(25):7980-92. | |||||
18 | Stereoselective chemoenzymatic synthesis of the four stereoisomers of l-2-(2-carboxycyclobutyl)glycine and pharmacological characterization at human excitatory amino acid transporter subtypes 1, 2, and 3. J Med Chem. 2006 Nov 2;49(22):6532-8. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.